{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:08:48Z","timestamp":1768086528892,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H10-No-006"],"award-info":[{"award-number":["H10-No-006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H14-Kokoro-017"],"award-info":[{"award-number":["H14-Kokoro-017"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H17-Kokoro-019"],"award-info":[{"award-number":["H17-Kokoro-019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H19-Nanji-Ippan-002"],"award-info":[{"award-number":["H19-Nanji-Ippan-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H20-Kokoro-022"],"award-info":[{"award-number":["H20-Kokoro-022"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H22-Nanji-Ippan-002"],"award-info":[{"award-number":["H22-Nanji-Ippan-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["13680918"],"award-info":[{"award-number":["13680918"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["14207106"],"award-info":[{"award-number":["14207106"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["AS232Z00009G"],"award-info":[{"award-number":["AS232Z00009G"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.braindev.2020.06.015","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:36:44Z","timestamp":1595990204000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chaperone therapy for molecular pathology in lysosomal diseases"],"prefix":"10.1016","volume":"43","author":[{"given":"Yoshiyuki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2020.06.015_b0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue","volume":"60","author":"De Duve","year":"1955","journal-title":"Biochem J"},{"key":"10.1016\/j.braindev.2020.06.015_b0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0016-5085(65)80041-5","article-title":"Inborn lysosomal diseases","volume":"48","author":"Hers","year":"1965","journal-title":"Gastroenterology"},{"key":"10.1016\/j.braindev.2020.06.015_b0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1098\/rstb.2003.1269","article-title":"Enzyme replacement therapy: conception, chaos and culmination","volume":"358","author":"Brady","year":"2003","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.braindev.2020.06.015_b0025","first-page":"7","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect Med Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2183\/pjab.90.145","article-title":"Emerging novel concept of chaperone therapies for protein misfolding diseases","volume":"90","author":"Suzuki","year":"2014","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.braindev.2020.06.015_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000112332","article-title":"Partial enzyme deficiencies: residual activities and the development of neurological disorders","volume":"6","author":"Conzelmann","year":"1983","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.braindev.2020.06.015_b0040","unstructured":"Oxford English Dictionary. 2nd ed. Oxford: Oxford University Press; 1989."},{"key":"10.1016\/j.braindev.2020.06.015_b0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0009-8981(82)90257-1","article-title":"Galactosialidosis (\u03b2-galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of \u03b2-galactosidase molecules","volume":"125","author":"Sakuraba","year":"1982","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.braindev.2020.06.015_b0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0014-4827(83)90175-1","article-title":"Effects of thiol protease inhibitors on intracellular degradation of exogenous \u03b2-galactosidase in cultured human skin fibroblasts","volume":"148","author":"Ko","year":"1983","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.braindev.2020.06.015_b0055","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1083\/jcb.111.3.857","article-title":"Quality control in the endoplasmic reticulum: folding and misfolding of vesicular stomatitis virus G protein in cells and in vitro","volume":"111","author":"de Silva","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1083\/jcb.117.3.505","article-title":"Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum","volume":"117","author":"Marquardt","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0006-291X(88)80038-X","article-title":"Cloning, sequencing, and expression of cDNA for human \u03b2-galactosidase","volume":"157","author":"Oshima","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0006-291X(90)91273-U","article-title":"Partial deletion of human \u03b1-galactosidase A gene in Fabry disease: direct repeat sequences as a possible cause of slipped mispairing","volume":"170","author":"Fukuhara","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0075","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant \u03b1-galactosidase gene product for the late-onset cardiac form of Fabry disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0080","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of \u03b1-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2020.06.015_b0090","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in GM1-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2020.06.015_b0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbadis.2004.03.007","article-title":"N-octyl-\u03b2-valienamine up-regulates activity of F213I mutant \u03b2-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease","volume":"1689","author":"Lin","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.braindev.2020.06.015_b0100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10545-006-0287-y","article-title":"\u03b2-Galactosidase deficiency: an approach to chaperone therapy","volume":"29","author":"Suzuki","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2020.06.015_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1379\/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2","article-title":"Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein","volume":"1","author":"Brown","year":"1996","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.braindev.2020.06.015_b0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2012.02.012","article-title":"Therapeutic chaperone effect of N-octyl-4-epi-\u03b2-valienamine on murine GM1-gangliosidosis","volume":"106","author":"Suzuki","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2020.06.015_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2020.06.015_b0120","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0387-7604(01)00216-9","article-title":"Galactonojirimycin derivatives restore mutant human \u03b2-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse","volume":"23","author":"Tominaga","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2020.06.015_b0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.braindev.2020.06.015_b0130","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1574893611666160212234924","article-title":"Chaperone therapy: New molecular therapy for protein misfolding diseases with brain dysfunction","volume":"11","author":"Suzuki","year":"2016","journal-title":"Curr Bioinformat"},{"key":"10.1016\/j.braindev.2020.06.015_b0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2020.06.015_b0145","series-title":"The online metabolic and molecular bases of inherited disease","article-title":"\u03b2-Galactosidase deficiency (\u03b2-galactosidosis): GM1-gangliosidosis and Morquio B disease","author":"Suzuki","year":"2013"},{"key":"10.1016\/j.braindev.2020.06.015_b0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1018573518127","article-title":"\u03b2-Galactosidase-deficient mouse as an animal model for GM1-gangliosidosis","volume":"14","author":"Matsuda","year":"1997","journal-title":"Glycoconj J"},{"key":"10.1016\/j.braindev.2020.06.015_b0155","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cbic.200900442","article-title":"Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin","volume":"10","author":"Luan","year":"2009","journal-title":"ChemBioChem"},{"key":"10.1016\/j.braindev.2020.06.015_b0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1039\/C4MD00270A","article-title":"Potent chemical chaperone compounds for GM1-gangliosidosis: N-substituted (+)-conduramine F-4 derivatives","volume":"6","author":"Kuno","year":"2015","journal-title":"MedChemComm"},{"key":"10.1016\/j.braindev.2020.06.015_b0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejmech.2016.09.095","article-title":"(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal \u03b2-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B","volume":"126","author":"Front","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0170","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.bmcl.2017.05.086","article-title":"A new type of pharmacological chaperone for GM1-gangliosidosis related human lysosomal \u03b2-galactosidase: N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols","volume":"27","author":"Schalli","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.braindev.2020.06.015_b0175","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.braindev.2020.06.015_b0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4161\/pri.2.4.7952","article-title":"Prion proteostasis: Hsp104 meets its supporting cast","volume":"2","author":"Sweeny","year":"2008","journal-title":"Prion"},{"key":"10.1016\/j.braindev.2020.06.015_b0185","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/hmg\/dds001","article-title":"Novel pharmacological chaperones that correct phenylketonuria in mice","volume":"21","author":"Santos-Sierra","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2020.06.015_b0190","doi-asserted-by":"crossref","first-page":"30493","DOI":"10.1074\/jbc.M803525200","article-title":"In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:glyoxylate aminotransferase","volume":"283","author":"Hopper","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0195","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1093\/hmg\/ddt217","article-title":"Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type","volume":"22","author":"Jorge-Finnigan","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2020.06.015_b0200","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0205","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.braindev.2020.06.015_b0210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1067389","article-title":"Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease","volume":"295","author":"Auluck","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.braindev.2020.06.015_b0215","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","article-title":"Protein-misfolding diseases and chaperone-based therapeutic approaches","volume":"273","author":"Chaudhuri","year":"2006","journal-title":"Febs J"},{"key":"10.1016\/j.braindev.2020.06.015_b0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138920110790909650","article-title":"Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases","volume":"11","author":"Nagai","year":"2010","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.braindev.2020.06.015_b0225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2174\/157015911798376226","article-title":"Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics","volume":"9","author":"Abisambra","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.braindev.2020.06.015_b0230","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijbiomac.2013.05.032","article-title":"Applying chaperones to protein-misfolding disorders: Molecular chaperones against \u03b1-synuclein in Parkinson's disease","volume":"60","author":"Chaari","year":"2013","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.braindev.2020.06.015_b0235","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/hmg\/10.14.1511","article-title":"Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice","volume":"10","author":"Cummings","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2020.06.015_b0240","doi-asserted-by":"crossref","first-page":"17193","DOI":"10.3390\/ijms160817193","article-title":"Protein folding and mechanisms of proteostasis","volume":"16","author":"D\u00edaz-Villanueva","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.braindev.2020.06.015_b0245","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","article-title":"Proteostasis impairment in protein-misfolding and -aggregation diseases","volume":"24","author":"Hipp","year":"2014","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0250","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1111\/febs.14576","article-title":"Molecular chaperones: from proteostasis to pathogenesis","volume":"285","author":"Ravindran","year":"2018","journal-title":"FEBS J"},{"key":"10.1016\/j.braindev.2020.06.015_b0255","first-page":"1598","article-title":"Life in the ER: wild nights, mounting stress and mid-40s burnout","volume":"148","author":"Harrison","year":"1993","journal-title":"CMAJ"},{"key":"10.1016\/j.braindev.2020.06.015_b0260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/bbrc.1997.7607","article-title":"KDEL receptor expression is not coordinatedly up-regulated with ER stress-induced reticuloplasmin expression in HeLa cells","volume":"240","author":"Llewellyn","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ceb.2010.11.002","article-title":"Chemical and\/or biological therapeutic strategies to ameliorate protein misfolding diseases","volume":"23","author":"Ong","year":"2011","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0270","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bmcl.2013.01.089","article-title":"Recent developments in targeting protein misfolding diseases","volume":"23","author":"Denny","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.braindev.2020.06.015_b0275","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/fmc.14.58","article-title":"Therapeutic targeting of misfolding and conformational change in alpha1-antitrypsin deficiency","volume":"6","author":"Nyon","year":"2014","journal-title":"Future Med Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molstruc.2016.06.046","article-title":"Mechanisms of protein misfolding: Novel therapeutic approaches to protein-misfolding diseases","volume":"1123","author":"Salahuddin","year":"2016","journal-title":"J Mol Struct"},{"key":"10.1016\/j.braindev.2020.06.015_b0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/path.5349","article-title":"Molecular mechanisms in chaperonopathies: clues to understanding the histopathological abnormalities and developing novel therapies","volume":"250","author":"Macario","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.braindev.2020.06.015_b0290","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138955708785132783","article-title":"Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning","volume":"8","author":"Leandro","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.braindev.2020.06.015_b0295","doi-asserted-by":"crossref","first-page":"F996","DOI":"10.1152\/ajprenal.00393.2015","article-title":"Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective","volume":"309","author":"Shayman","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.braindev.2020.06.015_b0300","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol Rev"},{"issue":"13","key":"10.1016\/j.braindev.2020.06.015_b0305","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2174\/1389450117666160307143345","article-title":"Pharmacoperones as a new therapeutic approach: in vitro identification and in vivo validation of bioactive molecules","volume":"17","author":"Ulloa-Aguirre","year":"2016","journal-title":"CDT"},{"key":"10.1016\/j.braindev.2020.06.015_b0310","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4939-8820-4_18","article-title":"Early stage discovery and validation of pharmacological chaperones for the correction of protein misfolding diseases","volume":"1873","author":"Aubi","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0315","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.neurol.2015.09.010","article-title":"Spreading of protein misfolding: A new paradigm in neurology","volume":"171","author":"Hauw","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.braindev.2020.06.015_b0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","article-title":"Protein misfolding in neurodegenerative diseases: implications and strategies","volume":"6","author":"Sweeney","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.braindev.2020.06.015_b0325","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.braindev.2020.06.015_b0330","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbpa.2018.05.018","article-title":"Therapeutic strategies for targeting neurodegenerative protein misfolding disorders","volume":"44","author":"Scannevin","year":"2018","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.braindev.2020.06.015_b0335","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1007\/s12035-018-1334-z","article-title":"Cellular Proteostasis in neurodegeneration","volume":"56","author":"Kurtishi","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.braindev.2020.06.015_b0340","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/revneuro-2016-0035","article-title":"Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics","volume":"30","author":"Gandhi","year":"2019","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.braindev.2020.06.015_b0345","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/boc.201800068","article-title":"Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease","volume":"111","author":"Martinez","year":"2019","journal-title":"Biol Cell"},{"key":"10.1016\/j.braindev.2020.06.015_b0350","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.conb.2020.02.009","article-title":"Potential benefit of manipulating protein quality control systems in neurodegenerative diseases","volume":"61","author":"Luh","year":"2020","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.braindev.2020.06.015_b0355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","article-title":"Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system","volume":"29","author":"Scarpa","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.braindev.2020.06.015_b0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/EBC20160005","article-title":"Cellular proteostasis: Degradation of misfolded proteins by lysosomes","volume":"60","author":"Jackson","year":"2016","journal-title":"Essays Biochem"},{"key":"10.1016\/j.braindev.2020.06.015_b0365","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: Lessons from Gaucher, GM1-gangliosidosis and Fabry diseases","volume":"52","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem Commun"},{"key":"10.1016\/j.braindev.2020.06.015_b0370","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.braindev.2020.06.015_b0375","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jnr.24558","article-title":"Proteostasis network alteration in lysosomal storage disorders: Insights from the mouse model of Krabbe disease","volume":"98","author":"Landi","year":"2019","journal-title":"J Neurosci Res"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760420301790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760420301790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:49:42Z","timestamp":1759952982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760420301790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0387760420301790"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2020.06.015","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chaperone therapy for molecular pathology in lysosomal diseases","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2020.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}